Prevalence and determinants of erectile dysfunction among male type 2 diabetes mellitus patients with chronic kidney disease: a cross-sectional study
Abstract
Background Erectile dysfunction (ED) is a common complication among patients with diabetes mellitus (DM) and chronic kidney disease (CKD). However, limited research has focused on the association between ED and CKD and, highlights a gap in addressing this issue. This study aimed to determine the prevalence of ED and identify the associated factors in patients with DM and CKD. Methods This cross-sectional study recruited 280 male patients, aged 18 years old and above, who had DM and CKD. Those with underlying psychiatry disorders, inability to understand Bahasa Malaysia, and on renal replacement therapy were excluded. The questionnaire contained demographic and clinical information and the Malay Version of the Hospital Anxiety and Depression Scale (HADS). Their sexual function was evaluated using the Malay Version of International Index of Erectile Function-5 (IIEF-5). The data was analyzed with simple and multiple logistic regressions. Results The prevalence of ED among DM patients with CKD was 95.0% (n=228). Metformin usage [adjusted odds ratio (adj. OR) =6.64; 95% confidence interval (CI): 1.54, 28.53; P=0.01], elevated urea levels (adj. OR =1.57; 95% CI: 1.10, 2.23; P=0.01), increased glycosylated hemoglobin (HbA1c) (adj. OR =1.75; 95% CI: 1.09, 2.82; P=0.02) and high educational attainment (adj. OR =0.21; 95% CI: 0.05, 0.88; P=0.03) were associated with ED among DM patients with CKD. Conclusions The prevalence of ED among patients with DM and CKD is high. Thus,…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 280 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.